Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Post-Trial Drug Access

Drugs

Locations

Clinical Specialty

361-380 of 847 trials

Hypertrophic Cardiomyopathy: Aficamten Study

We are evaluating the long-term safety and tolerability of aficamten in adults with hypertrophic cardiomyopathy. The study also looks at its effects on heart function in patients with obstructive HCM.

Hypertrophic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational MedicinesCardiologyInternal Medicine

Vedolizumab for Children with Moderate to Severe Crohn's Disease

We are studying how well different doses of vedolizumab help children and teenagers with Crohn's disease maintain their health. The goal is to see if it can keep symptoms under control and improve their overall well-being.

Crohn's Disease1-2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyPediatrics

Ulcerative Colitis and Crohn's Disease: Vedolizumab IV in Kids

We are studying the long-term safety of vedolizumab IV in children and teenagers with ulcerative colitis or Crohn's disease. This research aims to understand its effects on health and quality of life.

Active Ulcerative Colitis or Crohn's Disease>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterology

Small Cell Lung Cancer: AL8326 Treatment Study

We are evaluating the safety and effectiveness of the drug AL8326 for patients with small cell lung cancer who have already received prior treatment. This study aims to find the best dose and understand how well the drug works.

Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncologyPulmonology

Idiopathic Pulmonary Fibrosis: Buloxibutid Study

We are testing a new medication, buloxibutid, to see if it helps improve lung function and quality of life for people with idiopathic pulmonary fibrosis. The study compares its effects to a placebo over time.

Idiopathic Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Atopic Dermatitis in Children: Abrocitinib Study

We are investigating the effectiveness and safety of Abrocitinib for children aged 6 to under 12 with moderate-to-severe atopic dermatitis. The study will compare it to a placebo while using other topical treatments.

Moderate-to-Severe Atopic Dermatitis3-6 monthsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Partially RemoteAllergologyDermatology

Pulmonary Arterial Hypertension: Sotatercept Study

We are evaluating the long-term safety of sotatercept for adults with pulmonary arterial hypertension already on treatment. This study will help us understand how well it works when added to existing therapies.

Pulmonary Arterial Hypertension>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteCardiology

Advanced Solid Tumors: TransCon IL-2 β/γ Treatment Study

We are investigating the safety and tolerability of TransCon IL-2 β/γ alone and with other cancer therapies for adults with advanced solid tumors. This study aims to find the best dose and understand how it works in combination with existing treatments.

Advanced Solid Tumor Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Targeted Anti-Cancer Drugs: DRUP Trial

We are studying how well existing targeted drugs work for patients with advanced cancers that have specific genetic markers. This trial aims to improve access to effective treatments and gather important data on their use.

Non-Hodgkin LymphomaAdvanced Solid TumorT-cell Prolymphocytic Leukemia3-6 monthsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Sickle Cell Disease: Etavopivat Treatment Study

We are evaluating how well etavopivat works for adolescents and adults with sickle cell disease. The study aims to see if it improves symptoms and quality of life compared to a placebo.

Sickle Cell Disease>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematologyInternal Medicine

Thyroid Eye Disease: Efgartigimod PH20 SC

We are studying a new treatment for adults with thyroid eye disease to see if it reduces eye bulging compared to a placebo. This trial will help us understand its effectiveness and safety.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteEndocrinologyOphthalmology

Thyroid Eye Disease: Efgartigimod PH20 SC Study

We are testing a new treatment called efgartigimod PH20 SC in adults with thyroid eye disease. The goal is to see if it works better than a placebo in reducing symptoms.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteEndocrinologyOphthalmology

MOG Antibody-Associated Disease: Rozanolixizumab Study

We are studying whether Rozanolixizumab is effective and safe for adults with MOG antibody-associated disease. This research aims to provide insights into a potential new treatment for this condition.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteNeurology

Ulcerative Colitis in Kids: Ozanimod Study

We are testing the oral medication ozanimod in children with moderately to severely active ulcerative colitis who haven't responded to other treatments. The goal is to see if it helps improve their symptoms and overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyPediatrics

Alpha-1 Antitrypsin Deficiency: BEAM-302 Treatment Study

We are exploring a new treatment for adults with Alpha-1 Antitrypsin Deficiency-related lung or liver disease. The study aims to evaluate its safety and effectiveness in improving health outcomes.

Alpha-1 Antitrypsin Deficiency (AATD)>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteHepatologyPulmonology

Relapsing Multiple Sclerosis: Remibrutinib vs. Ocrelizumab

We are studying whether remibrutinib is as effective and safe as ocrelizumab for people with relapsing multiple sclerosis after switching treatments. This trial will help us understand the best options for managing the disease.

Relapsing Multiple SclerosisConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational MedicinesInternal MedicineNeurology

Pulmonary Arterial Hypertension: Ralinepag Study

We are studying the long-term safety and effects of ralinepag in patients with pulmonary arterial hypertension. This trial aims to see how it impacts walking ability, heart health, and overall quality of life.

Pulmonary HypertensionConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementCardiologyPulmonology

Long-Term Safety Study of Dabrafenib and Trametinib

We are evaluating the long-term safety of dabrafenib and trametinib for patients who have benefited from these treatments in previous studies. This study helps ensure continued access to these medications for those who need them.

Non-Small Cell Lung CancerMetastatic Melanoma1-2 yearsMonitoring phase (IV)6-10 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Complement 3 Glomerulopathy: Study of Iptacopan

We are evaluating the safety and effectiveness of iptacopan for patients with complement 3 glomerulopathy. The study aims to see if it can reduce protein levels in urine and improve kidney function.

C3 Glomerulopathy1-2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementNephrology

Lupus Nephritis: LNP023 Treatment Study

We are studying the safety and effectiveness of LNP023 in adults with active lupus nephritis. The goal is to see if it helps improve kidney function compared to standard treatments.

Lupus Nephritis1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational MedicinesNephrologyRheumatology

Search Clinical Trials in the European Union